1988
Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support.
Shea TC, Antman KH, Eder JP, Elias A, Peters WP, Schryber S, Henner WD, Schoenfeld DA, Schnipper LE, Frei E. Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. JAMA Dermatology 1988, 124: 878-84. PMID: 3288124, DOI: 10.1001/archderm.124.6.878.Peer-Reviewed Original ResearchConceptsAutologous bone marrow supportBone marrow supportHigh-dose combinationMarrow supportAgent chemotherapyPhase 2 doseMetastatic malignant melanomaOverall response rateMedian survivalComplete responsePartial responseSurgical resectionAdditional patientsMedian timeResidual tumorTreatment courseMalignant melanomaMarrow reconstitutionChemotherapyToxic reactionsPatientsResponse rateEntire groupMonthsDisease
1987
High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Journal Of The National Cancer Institute 1987, 71: 119-25. PMID: 3542208.Peer-Reviewed Original ResearchConceptsVeno-occlusive diseaseEvaluable patientsBreast cancerPrior treatmentAutologous bone marrow supportDose-limiting toxic effectFatal veno-occlusive diseaseCourses of cyclophosphamideDose level 4Bone marrow supportGood partial responseHigh-dose combinationDose level 5Metastatic breast cancerThree-drug combinationPolymorphonuclear leukocyte countAddition of melphalanHighest dose levelToxic effectsMarrow reinfusionMarrow supportPreparative regimenMost patientsPartial responseTransfusion independence